Since the beginning of the Covid pandemic, the number of horseshoe crabs bled for biomedical purposes has basically doubled, says Jay Bolden, senior director at Eli Lilly and Company. But a synthetic alternative has been available for more than 20 years. Grace Benninghoff reports:
Though the blood plays a critical role in drug safety testing, there are ongoing concerns about supply chain issues, ecosystem impacts and ethics. The synthetic alternative has been widely adopted in…
